Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Azd-4877. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 known ✓ | P52732 | 19/20 | 1.00 |
| ▸ | KIF23 | Q02241 | 1/20 | 1.00 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Azd-4877 SCHEMBL3867651 | 1.00 | KIF11 (1.00) | KIF11KIF23MAP1LC3BCYP3A4CYP2C19 | |
| Azd-4877 SCHEMBL360703 | 1.00 | KIF11 (1.00) | KIF11KIF23MAP1LC3BCYP3A4CYP2C19 | |
| Azd-4877 SCHEMBL3875692 | 0.99 | KIF11 (0.98) | KIF11KIF23MAP1LC3BCYP3A4CYP2C19 | |
| Azd-4877 SCHEMBL3875689 | 0.98 | KIF11 (0.97) | KIF11KIF23MAP1LC3BCYP3A4CYP2C19 | |
| SCHEMBL13871287 | 0.96 | KIF11 (0.92) | KIF11KIF23MAP1LC3BCYP3A4CYP2C19 | |
| SCHEMBL3870011 | 0.95 | KIF11 (0.91) | KIF11KIF23MAP1LC3BCYP3A4CYP2C19 | |
| SCHEMBL3863629 | 0.95 | KIF11 (0.91) | KIF11KIF23MAP1LC3BCYP3A4CYP2C19 | |
| SCHEMBL3863626 | 0.95 | KIF11 (0.91) | KIF11KIF23MAP1LC3BCYP3A4CYP2C19 | |
| Hydrochloric Acid SCHEMBL3875151 | 0.94 | KIF11 (0.89) | KIF11KIF23MAP1LC3BCYP3A4CYP2C19 | |
| SCHEMBL3869606 | 0.94 | KIF11 (0.88) | KIF11KIF23MAP1LC3BCYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2582682-B1 | MITOTIC KINESIN INHIBITORS FOR USE IN THE TREATMETNOF PULMONARY ARTERIAL HYPERTENSION | CYTOKINETICS INC (US) | 2015-01-14 | — | — | EP | claimed |
| US-20130210733-A1 | METHODS OF TREATING LUNG DISEASE | CYTOKINETICS, INC. | 2013-08-15 | — | — | US | claimed |
| EP-2582682-A1 | METHODS OF TREATING LUNG DISEASE | Cytokinetics, Inc. (US) | 2013-04-24 | — | — | EP | claimed |
| WO-2012009097-A1 | METHODS OF TREATING LUNG DISEASE | CYTOKINETICS, INC. (US) | 2012-01-19 | — | — | WO | claimed |
| US-20090099210-A1 | ENANTIOMERS OF SELECTED FUSED HETEROCYCLICS AND USES THEREOF | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | claimed |
| WO-2009037512-A1 | THERAPEUTIC METHODS 013 | ASTRAZENECA AB (SE) | 2009-03-26 | — | — | WO | claimed |
| US-7498333-B2 | Enantiomers of selected fused heterocyclics and uses thereof | ASTRAZENECA AB (SE) | 2009-03-03 | — | — | US | claimed |
| EP-2582682-B1 | MITOTIC KINESIN INHIBITORS FOR USE IN THE TREATMETNOF PULMONARY ARTERIAL HYPERTENSION | CYTOKINETICS INC (US) | 2015-01-14 | — | — | EP | disclosed |
| US-20130210733-A1 | METHODS OF TREATING LUNG DISEASE | CYTOKINETICS, INC. | 2013-08-15 | — | — | US | disclosed |
| EP-2582682-A1 | METHODS OF TREATING LUNG DISEASE | Cytokinetics, Inc. (US) | 2013-04-24 | — | — | EP | disclosed |
| WO-2012009097-A1 | METHODS OF TREATING LUNG DISEASE | CYTOKINETICS, INC. (US) | 2012-01-19 | — | — | WO | disclosed |
| US-20090099210-A1 | ENANTIOMERS OF SELECTED FUSED HETEROCYCLICS AND USES THEREOF | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| WO-2009037512-A1 | THERAPEUTIC METHODS 013 | ASTRAZENECA AB (SE) | 2009-03-26 | — | — | WO | disclosed |
| US-7498333-B2 | Enantiomers of selected fused heterocyclics and uses thereof | ASTRAZENECA AB (SE) | 2009-03-03 | — | — | US | disclosed |
| US-20080293744-A1 | Enantiomers of Selected Fused Pyrimidones and Uses in the Treatment and Prevention of Cancer | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | disclosed |
| WO-2008122798-A2 | PHARMACEUTICAL COMPOSITION OF AN EG5 INHIBITOR AND A MICROTUBULE INTERFERING AGENT FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | WO | disclosed |
| US-20080153854-A1 | NOVEL FUSED HETEROCYCLES AND USES THEREOF | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | US | disclosed |
| US-20060063751-A1 | Novel fused heterocycles and uses thereof | ASTRAZENECA AB (SE) | 2006-03-23 | — | — | US | disclosed |
| US-20060041129-A1 | Enantiomers of selected fused heterocyclics and uses thereof | ASTRAZENECA AB (SE) | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063751-A1 | Novel fused heterocycles and uses thereof | RB1, CDK19, PRMT9 | KIF11 1978/4885KIF23 2194/4885MAP1LC3B 3998/4885 |
| US-20080153854-A1 | NOVEL FUSED HETEROCYCLES AND USES THEREOF | RB1, CDK19, PRMT9 | KIF11 1978/4885KIF23 2194/4885MAP1LC3B 3998/4885 |
| US-20080293744-A1 | Enantiomers of Selected Fused Pyrimidones and Uses in the Treatment and Prevention of Cancer | DHFR, DPYD, TYMS | KIF11 3865/4885KIF23 3813/4885MAP1LC3B 4356/4885 |
| US-20090099210-A1 | ENANTIOMERS OF SELECTED FUSED HETEROCYCLICS AND USES THEREOF | CYP11B2, HCCS, CYP11B1 | KIF11 3171/4885KIF23 3405/4885MAP1LC3B 3465/4885 |
| US-20060041129-A1 | Enantiomers of selected fused heterocyclics and uses thereof | CYP11B2, HCCS, CYP11B1 | KIF11 3171/4885KIF23 3405/4885MAP1LC3B 3465/4885 |
| US-20130210733-A1 | METHODS OF TREATING LUNG DISEASE | KIF5B, KIF2C, KIF18B | KIF11 12/4885KIF23 6/4885MAP1LC3B 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.